A unique cytotoxic CD4⁺ T cells signature defines critical COVID-19

- 2 Sarah Baird^{1,2†}, Caroline L. Ashley^{1,2†}, Felix Marsh-Wakefield^{1,3}, Sibel Alca^{1,2}, Thomas M.
- 3 Ashhurst^{1,4}, Angela L. Ferguson¹, Hannah Lukeman^{1,2}, Claudio Counoupas^{1,5}, Jeffrey J. Post⁶,
- 4 Pamela Konecny⁷, Adam Bartlett^{8,9,10}, Marianne Martinello⁸, Rowena A. Bull^{8,9}, Andrew Lloyd⁸,
- 5 Alice Grey¹¹, Owen Hutchings¹¹, Umaimainthan Palendira¹, Warwick J. Britton^{5,12}, Megan
- 6 Steain^{1,2*} & James A. Triccas^{1,2*}

1

7

- 8 ¹School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney,
- 9 Camperdown, NSW, Australia
- ²Sydney Institute for Infectious Diseases and the Charles Perkins Centre, The University of Sydney,
- 11 Camperdown, NSW, Australia
- ³Vascular Immunology Unit, The University of Sydney, Sydney, New South Wales, Australia
- ⁴Sydney Cytometry Core Research Facility, Charles Perkins Centre, Centenary Institute and The
- 14 University of Sydney
- ⁵Tuberculosis Research Program, Centenary Institute, Sydney, NSW, Australia
- ⁶Prince of Wales Clinical School, UNSW Australia, Sydney, NSW Australia
- ⁷St George Hospital, Sydney, New South Wales, Australia
- ⁸The Kirby Institute, UNSW, Sydney, NSW, Australia
- ⁹School of Biomedical Sciences, Faculty of Medicine, UNSW, Sydney, NSW, Australia
- 20 ¹⁰Sydney Children's Hospital, Sydney, NSW, Australia
- 21 ¹¹RPA Virtual Hospital, Sydney Local Health District, Sydney, NSW, Australia.
- 22 ¹²Department of Clinical Immunology, Royal Prince Alfred Hospital, Camperdown, Australia
- ^{*}Address correspondence to James A. Triccas; jamie.triccas@sydney.edu.au or Megan Steain;
- 25 <u>megan.steain@sydney.edu.au</u>

23

26

- [†]These authors contributed equally to this work
- 30 Running title: Cytotoxic T cells and COVID-19 severity

Abstract

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Background and objectives. SARS-CoV-2 infection causes a spectrum of clinical disease presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses correlate with protection against symptomatic and severe infection, the contribution of the T cell response to the resolution or progression of disease is still unclear. Optimal protective immunity may require activation of distinct immune pathways. As such, defining the contribution of individual T cell subsets to disease outcome is imperative to inform the development of nextgeneration COVID-19 vaccines. To address this, we performed immunophenotyping of T cell responses in unvaccinated individuals, representing the full spectrum of COVID-19 clinical presentation. Methods. Spectral cytometry was performed on peripheral blood mononuclear cell samples from patients with PCR-confirmed SARS-CoV-2 infection. Computational and manual analyses were used to identify T cell populations associated with distinct disease states through unbiased clustering, principal component analysis and discriminant analysis. Results. Critical SARS-CoV-2 infection was characterised by an increase in activated and cytotoxic CD4⁺ (CTL) cells of a T follicular helper (T_{FH}) or effector memory re-expressing CD45RA (T_{EMRA}) phenotype. These CD4⁺ CTLs were largely absent in those with less severe disease. In contrast, those with asymptomatic or mild disease were associated with high proportions of naïve T cells and reduced expression of activation markers. Conclusion. Highly activated and cytotoxic CD4⁺ T cell responses may contribute to cell-mediated host tissue damage and progression of COVID-19. Potential for induction of these detrimental T cell responses should be considered when developing and implementing effective COVID-19 control strategies.

Keywords. SARS-CoV-2, COVID-19, T cells, Spectral Cytometry, CD4-CTLs.

Introduction

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been ongoing since March of 2020. As of February 2023, over 754 million cases of SARS-CoV-2 infection and 6.83 million fatalities from coronavirus disease 2019 (COVID-19) have been reported. While several vaccines are now available for use, SARS-CoV-2 remains a leading cause of infectious disease death globally. One of the major challenges with SARS-CoV-2 infection is the spectrum of COVID-19 clinical presentation, ranging from asymptomatic to fatal. It is thought that more severe disease results from a dysregulated immune response to infection; however, variability in this immune dysfunction between individuals has limited understanding of the correlates of disease severity. Developing a more comprehensive understanding of the immune response across the spectrum of COVID-19 clinical presentation will help to differentiate protective from pathogenic immune responses. This is essential to inform the development of next-generation therapies and vaccines against SARS-CoV-2, with improved longevity and efficacy against newly emerging variants of concern (VOC). The key correlate of protective immunity against infection and severe disease in COVID-19 is neutralising antibody responses (NAb).^{2,3}As such, the factors that contribute to breakthrough infection following vaccination centre around humoral immune responses, such as waning NAb titres, and antibody escape mutations on globally dominant VOC. 4-9 The T cell response appears to have greater longevity than detectable NAbs, with sustained response to antigen stimulation demonstrated >1-year post-infection. 10,11 Additionally, the dominant T cell epitopes do not overlap with areas of high mutation on variant viruses, and as a result the T cell response is preserved against antibody-escape VOC. 9,12-16 Considering the limitations of current vaccines, it has been suggested that the long-lived T cell response against SARS-CoV-2 variants may contribute to protective immunity in the absence of a robust humoral immune response. 12,13,16 While NAb responses have been shown to tightly correlate with protection against disease, no such correlation

has been shown with the T cell response to SARS-CoV-2.¹⁷ There is evidence that polyfunctional and cross-reactive T cell responses to seasonal coronaviruses are associated with milder disease and faster viral clearance.^{18–20} However, several studies have also described an expansion of highly activated T cells in severe COVID-19, that could potentially contribute to excessive inflammatory immune responses and host-tissue damage.^{21–23} As such, whether T cells play a protective or pathogenic role in COVID-19 is still unresolved.

To better define the role of T cell subsets, we performed an explorative investigation into T cell phenotypes across the clinical spectrum of COVID-19 presentation, utilising an unbiased analysis approach with a T-cell-centric high-dimensional cytometry panel. We report that critical COVID-19 infection is characterised by a shift from naïve T cell phenotypes to an expansion of cytotoxic CD4⁺T lymphocyte subsets.

Results

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

The T cell compartment distinguishes critical SARS-CoV-2 infection from other disease states. To obtain a global view of the T cell response within and between disease states, peripheral blood mononuclear cells (PBMCs) were isolated from the blood of patients and spectral cytometry was performed using a T cell-centric antibody panel. Initially, T cell populations were manually gated (Figure s1) and differences in the proportion of each population between patients were identified by an unsupervised Principal Component Analysis (PCA), where each data point represents one patient sample (Figure 1a). When the COVID-19 severity of each patient was superimposed onto the PCA patients with critical infection separated distinctly across the first component (dim 1, accounted for 31.8% of the variance) from most other patient samples (Figure 1a). Visualisation of the contribution of each T cell population proportion to the principal components revealed that the expression of activation/proliferation markers HLA-DR, Granzyme B (GZMB), Perforin (PFN), and Ki-67 on central memory (T_{CM}), effector memory (T_{EM}), and effector memory re-expressing CD45RA (T_{EMRA}) contribute to the separation of samples in dimension 1 (Figure 1b). Furthermore, the proportions of these activated, memory CD4⁺ and CD8⁺ T cell subsets were negatively correlated to those of CD4⁺ and CD8⁺ naïve T cells (T_N) (Figure 1b). Metaclusters of cytotoxic CD4⁺ T cells differentiate critical and severe SARS-CoV-2 infection To determine which T cell populations may be implicated in progression from severe to critical COVID-19, patients in those groups were selected for further analysis. To fully capture the heterogeneity of activation and cytotoxic marker expression in the T cell compartment of these patients, unbiased clustering was performed. FlowSOM clustering was set to create 25 metaclusters (Mcs) and fast interpolation-based t-SNE (Fit-SNE) was used to visualise the proportion of each Mc (Figure 2a & b), with a heatmap generated for phenotyping (Figure 2c). As the T-cell panel included markers to define conventional CD4⁺ and CD8⁺ subsets, CD4⁻CD8⁻ Mcs (7, 8, 11, 14 and

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

22) were excluded and a Partial Least Squares Discriminant Analysis (PLS-DA) was performed to identify the Mcs that contribute to variance between severe and critical infection. Like the PCA (Figure 1b) the PLS-DA revealed distinct separation of severe and critical patients, with 43.6% of the variance in the proportion of Mcs accounted for in the first component (Figure 2d). Mc25, 15, and 5 were enriched in critical infection, with Mc23 and 2 enriched in severe infection patients (Figure 2e & b). To confirm that the difference in these Mcs were not an artefact of the unsupervised nature of the PLS-DA, unpaired Mann-Whitney U-tests comparing the proportions of each Mc between severe and critical patients was performed. Mc25 (GZMB⁺PFN⁺ CD4⁺ CD45RO⁻, CCR7⁻), Mc15 (GZMB⁺PFN⁺ CD4⁺ CD45RO⁺, CCR7⁻), and Mc5 (HLA-DR⁺ CD4⁺ CD45RO⁺, CCR7⁺) were significantly enriched in critical compared to severe infection (Figure 2f). While the expression of CCR7 and CD45RO on Mc25 and 15 suggest a T_{EMRA} and T_{EM} phenotype respectively, these Mcs also appeared to express intermediate levels of CXCR5 on the heatmap, a feature of CD4⁺ T_{FH} cells (Figure 2c). However, Mcs 25 and 15 displayed a spectrum of expression of CXCR5 (Figure s2) and thus this analysis did not allow definitive determination of T_{FH} phenotype. Therefore, Mc25 and 15 represent cytotoxic CD4⁺ T lymphocyte subsets, with Mc5 being a population of activated T_{CM} cells. The proportion of Mc23 (CD8⁺ CD45RO⁻, CCR7⁺) and Mc2 (CD4⁺ CD45RO, CCR7⁺) were significantly greater in severe patients than critical, representing non-activated naïve (T_N) CD8⁺ and CD4⁺ T cells, respectively (Figure 2f). This analysis suggests an expansion of activated and cytotoxic CD4⁺T cells populations and a decrease in the proportion of T_N cell subsets is involved in progression from severe to critical SARS-CoV-2 infection.

Cytotoxic CD4⁺ T lymphocytes are characteristic of disease progression

As the proportions of naïve and memory T cells were negatively correlated (Figure 1c), the distribution of naïve/memory subsets were further explored in the CD4⁺ non-T_{FH} and CD8⁺ T cell compartments by manual gating on CD45RO and CCR7 (Figure 3a). Critical patients exhibited

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

increased proportions of CD8⁺ T_{EMRA} cells and a reduction in the proportion of CD4⁺ T_N cells, compared to both mild and severe disease (Figure 3b). In contrast, the T cell compartments in asymptomatic, mild, moderate, and severe patients were composed of comparable proportions of T_N CD4⁺ and CD8⁺ cells. While the proportion of CD4⁺ T_{EMRA} cells was not significantly elevated, critical patients had increased expression of the activation marker HLA-DR on CD4⁺ T_{EMRA} cells compared to those with asymptomatic or mild disease (Figure 3c). There was also a notable increase in the proportion of CD8⁺ T_{EMRA} cells expressing the activation marker PD-1 as disease severity worsened (Figure 3c). As Mc25 and 15 could not clearly be defined as T_{FH} cell populations, manually gated CXCR5^{hi} CD4⁺ T_{FH} cells were selected for further analysis. While the proportion of total T_{FH} and CCR7⁺PD-1⁻ T_{FH} cells was not significantly different between groups, the proportion of circulating PD-1⁺CCR7⁻T_{FH} cells (cT_{FH}) was elevated in critical infection (Figure 3d). The computational analyses in Figures 1 and 2 revealed distinct populations of cytotoxic (GZMB⁺PFN⁺) CD4⁺ T cell subsets enriched in critical disease. As cytotoxic CD8⁺ T cells have been correlated with disease severity and mortality in COVID-19,²² the proportion of GZMB⁺PFN⁺ CD4⁺ and CD8⁺ subsets were of interest to investigate further. As a proportion of lymphocytes, critical patients had expanded populations of cytotoxic CD4⁺, but not CD8⁺ T cells. Cytotoxic CD4⁺ T cells made up a mean of 3.68% of the lymphocyte compartment in critical infection patients, and between 0.41-1.28% in all other disease states (Figure 4a). To delineate the subsets of cytotoxic CD4⁺ T cells contributing to this, the proportions of GZMB⁺PFN⁺ T_{FH} and CD4⁺ non-T_{FH} cells were compared across disease states. Both these subsets were significantly elevated in critical disease, and as such the phenotype of subpopulations within these subsets were explored further (Figure 4b). Of the CD4⁺ non-T_{FH} cell compartment, there was a higher proportion of CD4⁺ T_{EMRA} cells expressing GZMB⁺PFN⁺ cells in critical infection (Figure 4c). This was in line with the predominant T_{EM} and T_{EMRA} phenotype of cytotoxic compared to total CD4⁺ non-T_{FH} cells, which were largely of a T_N and T_{CM} phenotype (Figure 4d). Similarly, cytotoxic CD4⁺ T_{FH} cells were

almost exclusively of a CCR7 PD-1 $^+$ cT_{FH} phenotype and total T_{FH} cells were predominantly of a CCR7 $^+$ PD-1 $^-$ phenotype (Figure 4e). Finally, the proportion of cytotoxic CD4 $^+$ and CD8 $^+$ T cells was correlated to determine whether CD4 $^+$ cytotoxicity may be a compensating for CD8 $^+$ T cell exhaustion. However, these two populations correlated positively with each other (p = 0.0039: Figure 4f). From these data it appears that the expansion of cytotoxic CD4 $^+$ cT_{FH} and T_{EMRA} populations during SARS-CoV-2 infection is unique to critical disease.

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

Discussion Characterising immune responses that associate with different disease severities of COVID-19 may help to define protective immune responses to SARS-CoV-2 and guide the rational development of next-generation vaccines. This study provides a phenotypic analysis of the T cell response in patients experiencing asymptomatic to critical SARS-CoV-2 infection. We confirm that the T cell compartment is distinctly altered in critical SARS-CoV-2 infection, defined by an expansion of effector memory subsets, and increased expression of activation and cytotoxic functional markers on CD4⁺ T cells. These data suggest a potentially pathogenic role of cytotoxic CD4⁺ CTLs in the progression of COVID-19. CD4⁺ T cells are well-established critical responders in viral infection; however, CTL function is more commonly associated with CD8⁺ T cell populations. As such, it is of interest that the top Mcs associated with the progression of disease from severe to critical were activated and cytotoxic CD4⁺ T cell populations (Figure 2). CD4⁺ T cells can mediate host-cell death through secretion of granzyme B and perforin^{24,25}, and CD4⁺ CTLs have been identified during viral infections including human immunodeficiency virus (HIV), human cytomegalovirus (CMV), Epstein Barr virus (EBV), influenza, dengue virus and more recently SARS-CoV-2.26 In patients with COVID-19, CD4 T cells expressing high levels of PFN1, GZMB and GZMH transcripts have been identified previously by scRNA-seq to be enriched in hospitalised compared to non-hospitalised COVID-19 patients.²⁷ The data provided in this current study describes an increase in CD4⁺ CTLs, and a unique expansion of GZMB+PFN+ CD4 T_{EMRA} cells during critical infection at the level of protein expression. While the circulating T cell populations have been analysed in this cohort, high infiltration of CD4⁺ CTLs, as well as CD8⁺ CTLs, have also been reported in the lung parenchyma of severely ill COVID-19 patients.^{24,28} The elevated expression of HLA-II in the respiratory

epithelium provides a potential mechanistic basis for the role of CD4⁺ CTLs in the profound host

tissue damage associated with SARS-CoV-2 acute respiratory distress syndrome (ARDS).²⁴

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

In the CD4 T_{FH} cell compartment, critical patients also exhibited increased proportions of cytotoxic cells, which were predominantly of a CCR7 PD-1 phenotype; such cells have been previously described as circulating T_{FH} (cT_{FH}) cells.²⁹ Cytotoxic T_{FH} cells have been shown to induce B cell death and to correlate negatively with antibody titres in recurrent Strep A infection in children.³⁰ Post-mortem investigations have shown loss of germinal centre (GC) B cells and absence of GCs in the lymph nodes of COVID-19 decedents. ³¹ However, while cytotoxic cT_{FH} cells were elevated and correlated negatively to anti-S1/S2 SARS-CoV-2 antibodies in hospitalised patients, this correlation was not seen in non-hospitalised patients.²⁷ Conversely, antibody-secreting plasmablasts have been correlated with mortality in COVID-19.²² and higher antibody responses are associated with more severe disease.³² As there are limited studies investigating cytotoxic cT_{FH} in COVID-19, the implications of cytotoxicity in cT_{FH} cells require further investigation to assess any potential detrimental effect this cell type may have on antibody responses to SARS-CoV-2. CD4⁺ T cell cytotoxicity has been proposed to be a compensatory mechanism to combat exhaustion of CD8⁺ T cells, in which CD8⁺ CTL expression of GZMB and PFN decrease, and PD-1 increases. 33,34 In contrast, no change in the proportion of CD8+ GZMB+PFN+ subsets was observed here across disease severities. Moreover, PD-1 expression was not highlighted as a key variable in the separation of disease states in the PCA. This suggests that if CD8⁺ CTL exhaustion was present it was not a differentiating feature of disease progression. As such, the increased proportion of PD-1⁺CD8⁺ T_{EMRA} cells in critical infection likely represents a phenotype of increased activation, rather than functional exhaustion. In line with this view, previous studies have reported elevated frequencies of hyperactivated CD8⁺ cells, defined by expression of HLA-DR⁺CD38⁺PD-1⁺TIM-3⁺, in severe and critical SARS-CoV-2 infection. 21,22 While no difference in cytotoxicity was reported here, GZMB and PFN expression has been correlated with critical disease and mortality in COVID-19. 22,35-39 Rha et al., (2021) reported GZMB and PFN were expressed by almost all SARS-CoV-2-

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

specific multimer⁺ CD8⁺ T cells. 40 As such, enrichment for SARS-CoV-2 specific T cells may provide more insight into the changes in proportion and phenotype of cytotoxic CD8⁺ T cells between disease states. In combination with these studies, the data presented here suggest that hyperactivated effector memory subsets of CD8⁺ T cells may contribute to COVID-19 progression. Investigating the immune response in asymptomatic and mild disease can shed light on the immune response that effectively controls viral replication and disease progression. Control of viral load by T cells was demonstrated in B-cell depleted Rhesus Macaques ⁴¹, and CD8⁺ T cell responses correlated with better clinical outcome in patients with inborn errors in humoral immune responses and B cell impairment in SARS-CoV-2 infection. 42,43 In the current study, asymptomatic and mild patients exhibited low frequencies of activated or cytotoxic cells, and a predominantly naïve phenotype in both the CD4⁺ and CD8⁺ compartments. However, there is an inherent limitation to investigating the peripheral immune response in a respiratory infection where localised inflammation and resident immune cell responses may not be reflected in circulation.⁴⁴ Furthermore, this study did not investigate SARS-CoV-2-specific T cells, and as such a proportionally smaller T cell response may be missed in these less severe disease states. It has been shown previously that individuals with mild infection are less likely to have detectable SARS-CoV-2-specific T cell responses. 45 In combination with the relative lack of a robust T cell response in asymptomatic and mild disease here, this may question the necessity of a strong T cell response to prevent the progression of COVID-19. This is consistent with the diverse polyclonal, less differentiated SARS-CoV-2 specific T cell response observed in children with mild and asymptomatic T cell response than the clonally expanded memory T cell response with markers of cytotoxicity and exhaustion present in adults. 46 The protective capacity of T cells should be investigated further to assess whether preserved T cell response against variant SARS-CoV-2 viruses provide protection against severe disease, as has been suggested previously. 12,13,16

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

Finally, there are several clinical variables that may confound this analysis, notably the impact of age on the immune response to infection. The critical patients were older than asymptomatic and mild patients which is reflective of the high median age of COVID-19 patients admitted to hospital and ICU. 47 Age over 65 years is associated with a progressive decline in immune function characterised by decreased thymic function, contraction of naive T cell populations, and perturbed T cell function, such as reduced cytokine production and proliferative capacity. 48,49 It has been shown previously that SARS-CoV-2 immune dysregulation mimics that seen in age-related immunosenescence.⁵⁰ Without age-matched patients, the impact of age cannot be extricated from that of disease severity on the T cell response to SARS-CoV-2. The data presented in our study add to our understanding of the contribution of T cell responses to disease progression in SARS-CoV-2 infection. The distinct absence of a notable T cell response in asymptomatic disease but expansion of cytotoxic CD4+ cT_{FH} and T_{EMRA} subset in critical disease, suggest that CTLs may be contributing to host tissue damage and systemic inflammatory disease. As such, the potentially detrimental role of T cell responses in COVID-19 should be considered in the development of next-generation therapies and vaccines against SARS-CoV-2.

Material and Methods

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

Patient Demographics SARS-CoV-2 PCR-positive patients and their household contacts were enrolled through the Royal Prince Alfred (RPA) hospital COVID-19 clinic or virtual care system in March of 2020 (COVIMM cohort). Ethics approval was granted by the RPA ethics committee, human ethics number X20-0117 and 2020/ETH00770. Verbal consent was given by all participants. Additional patients enrolled in the COSIN study in June 2021 through seven hospital microbiology labs, and out-patient care units across Sydney, Australia, as described by Balachandran et al. (2022) were also included. Ethics approval was granted by Human Research Ethics Committees of the Northern Sydney Local Health District and the University of New South Wales, NSW Australia (ETH00520), and written consent was obtained from all patients. SARS-CoV-2 infection was defined by a positive nasopharyngeal RT-PCR performed by accredited laboratories within the Sydney Health District. Patients were classified as asymptomatic (n = 5), mild (n = 18), moderate (n = 4), severe (n = 5), or critical (n = 3) (Supplementary Table 1). COVID-19 disease severity defined by the NIH as guidelines (https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/). **Patients** were classified as mild if their symptoms were self-manageable. Immunophenotyping by spectral cytometry Patient PBMCs were isolated from whole blood by Ficoll-density gradient separation, and cryopreserved in Heat-inactivated FBS with 10% DMSO at -80°c. Cryopreserved PMBC samples were thawed and diluted to a concentration of 1 x 10⁶ live PMBCs in RMPI supplemented with 10% FCS and 100 ug/ml streptomycin and penicillin in a U-bottom 96-well plate. Cells were washed in FACS buffer, dead cells labelled with LIVE/DEADTM Fixable Blue dye (Invitrogen) for 20 minutes at 4°C and washed twice in FACS buffer. Cells were stained with extracellular markers (Supplementary Table 2; CD3-BUV395 (1:20), CD4-PerCPCy5.5 (1:100), CD8-BUV496 (1:100),

296

297

298

299

300

301

302

303

304

305

306

307

308

309

317

318

319

CD19-BV510 (1:50), CD56-BV605 (1:50), HLA-DR-BV650 (1:50), CD45RO-BV786 (1:50), CD197-PECy7 (1:20), and CXCR5-AF647 (1:20) in FACS buffer for 20 minutes at 4°C. Cells were then permeabilised and fixed with Transcription Factor Buffer Set (BD PharmingenTM) for 40 minutes at 4°C. Cells were washed then stained with intracellular markers (Supplementary Table 2) PD-1-BV737 (1:50), Ki-67-BV711 (1:50), Perforin-PE (1:50), and Granzyme B-APC (1:20) in Transcription Factor wash buffer (BD PharmingenTM). Anti-Mouse Ig, κ/Negative Control Particles Set (BDTM CompBeads) were used for single stain controls and stained with corresponding extracellular and intracellular stains. Fluorescent minus one (FMO) controls were included for intracellular markers and stained at the concentration of patient samples at corresponding staining times. The samples underwent a second fixation step with 4% paraformaldehyde for 30 minutes, washed, and resuspended in 200 ml FACS buffer for acquisition. Patient samples and controls were acquired using the 5-laser Cytek Aurora® Spectral Cytometer. Spectral unmixing was performed using the inbuilt SpectroFlo® software after acquisition of unstained and single-stained controls and before patient sample acquisition. **Data Analysis**

Data analysis was performed in FlowJo v10.8.1, R v4.2.1, and GraphPad Prism v9. Dead cells, doublets, and debris were excluded in FlowJo v10.8.1 by FSC-A, FSC-H, SCC-A, and LIVE/DEAD dye (Figure S1). NKT and B cells were excluded by CD3⁺CD56⁺ and CD3⁻CD19⁺ phenotype, respectively. Compensation for unmixing errors was performed in FlowJo v10.8.1. Irregularities in staining and acquisition between batches were controlled by matching gates on control samples and applying identical gate lineage and functional marker expression within each staining batch.

To control for the differences between staining batches, the Principal Component Analysis (Figure 1) was calculated using 38 overlapping CD3⁺ T cell populations that were manually gated in FlowJo v10.8.1. CD4⁺ and CD8⁺ T cells were first divided into T_N (CCR7⁺CD45RO⁻), T_{CM}

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

(CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), T_{EMRA} (CCR7⁻CD45RO⁻) subsets. The frequency of CD4⁺ and CD8⁺ T_N, T_{CM}, T_{EM}, and T_{EMRA} subsets, and the cells expressing HLA-DR, PD-1, GRZMB, PFN, and Ki-67 in the T_{CM}, T_{EM}, and T_{EMRA} subsets were included to assess the significance of T cell function on disease status (Figure S2). Each population was calculated as a proportion of its respective CD4⁺ or CD8⁺ T cell compartment, and these frequencies were used for PCA analysis in R v4.2.1 using the Spectre package.⁵¹ For the comparison between severe and critical infection, the R package Spectre was utilised for computational analyses (https://www.ncbi.nlm.nih.gov/pubmed/33840138). CD3⁺ T cells were exported for each patient sample. FlowSOM clustering created 25 metaclusters. Fit-SNE dimensionality reduction⁵² was run on subsampled data of 50,000 cells from severe and critical groups to create a representative plot between disease states and a heatmap plot of cellular marker expression on each metacluster was created using the pheatmap function. To identify contributions to differences between severe and critical infection, a partial least squares discriminant analysis (PLS-DA) was done. 53 To validate the phenotype of metaclusters, an FCS file of marker expression on each metacluster was created using the write files function in Spectre. This allowed for clear analysis of marker expression for each metacluster in FlowJo v10.8. After exclusion of CD4 CD8 FlowSOM metaclusters, PLS-DA was performed to identify the variability in proportion of metaclusters between severe and critical disease. Validation of the statistical differences in proportion of metaclusters between groups was performed in GraphPrism v9. The difference between groups were analysed by two-sided paired Mann-Whitney U-test, and nonparametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original False Discovery Rate (FDR) method of Benjamini and Hochberg. Statistical significance between groups in computational analyses were calculated with a permutation ANOVA, with correction for multiple comparisons by FDR method. Statistical significance was set as $p \le 0.05$.

Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Acknowledgments This work was supported by MRFF COVID-19 Vaccine Candidate Research Grant 2007221 (J.A.T., C.C., M.S., A.L.F.). F.M. □ W. and T.M.A. are supported by the International Society for the Advancement of Cytometry (ISAC) Marylou Ingram Scholars program. COSIN cohort was supported by Snow Medical Foundation as an investigator-initiated study. We acknowledge the support of the University of Sydney Advanced Cytometry Facility. The authors thank the study participants for their contribution to this research and the clinical staff who collected the samples.

References

- 362 1. WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. 2022.
- 363 2. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
- antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
- infection. Nat Med. 2021; **27**: 1205–1211.
- 366 3. Cromer D, Steain M, Reynaldi A, Schlub TE, Sasson SC, Kent SJ, et al. Neutralising
- antibodies predict protection from severe COVID-19. Nat Comms. 2023 In Press.
- 368 4. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced
- neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021; **184**:
- 370 4220-4236.e13.
- 5. Favresse J, Bayart JL, Mullier F, Elsen M, Eucher C, van Eeckhoudt S, et al. Antibody titres
- decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect. 2021; **10**: 1495-
- 373 1498.
- 374 6. Vanshylla K, di Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, et al.
- 375 Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in
- humans. Cell Host Microbe. 2021: **29**: 917-929.e4.
- 7. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, le Bert N, et al. Dynamics of SARS-CoV-
- 378 2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet
- 379 Microbe. 2021; **2**: 240-249
- 380 8. Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-
- 381 1273 vaccine–induced antibodies against SARS-CoV-2 variants. Science (1979). 2021; 373:
- 382 1372-1377.
- 383 9. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-
- 384 CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19
- convalescent donors and vaccinees. Sci Immunol. 2021; **6**: 782-787.

- 386 10. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, et al. SARS-CoV-2-specific T cell
- memory is sustained in COVID-19 convalescent patients for 10 months with successful
- development of stem cell-like memory T cells. Nat Commun. 2021; 12.
- 11. Lu Z, Laing ED, Pena DaMata J, Pohida K, Tso MS, Samuels EC, et al. Durability of SARS-
- 390 CoV-2–Specific T-Cell Responses at 12 Months Postinfection. J Infect Dis. 2021; **224**: 2010–
- 391 9.
- 392 12. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination
- induces immunological T cell memory able to cross-recognize variants from Alpha to
- 394 Omicron. Cell. 2022; **185**: 847-859.e11.
- 395 13. Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2
- variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals.
- 397 Cell Rep Med. 2021; **2**: 100355.
- 398 14. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad
- 399 CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. Journal of
- 400 Clinical Investigation. 2021; **131**: e149335
- 401 15. Boni C, Cavazzini D, Bolchi A, Rossi M, Vecchi A, Tiezzi C, et al. Degenerate CD8 Epitopes
- Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out
- From the SARS-CoV-2 Variants Storm. Front Immunol. 2021; **12**: 730051.
- 404 16. Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, et al. Structure-guided
- T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021; **184**: 4401-
- 406 4413.e10.
- 407 17. Kent SJ, Khoury DS, Reynaldi A, Juno JA, Wheatley AK, Stadler E, et al. Disentangling the
- 408 relative importance of T cell responses in COVID-19: leading actors or supporting cast? Nat
- 409 Rev Immunol. 2022; **28**: 387-397.

- 410 18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.
- 411 Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations
- with Age and Disease Severity. Cell. 2020; **183**: 996-1012.e19.
- 413 19. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive features of
- SARS-CoV-2-specific T cells predict recovery from severe COVID-19. Cell Rep. 2021; **36**:
- 415 109414.
- 416 20. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory
- T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat
- 418 Commun. 2022; **13**: 80.
- 419 21. Laing AG, Lorenc A, del Molino del Barrio I, Das A, Fish M, Monin L, et al. A dynamic
- 420 COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020; **26**:
- 421 1623–35.
- 422 22. Kuchroo M, Huang J, Wong P, Grenier JC, Shung D, Tong A, et al. Multiscale PHATE
- identifies multimodal signatures of COVID-19. Nat Biotechnol. 2022; **40**: 681-691.
- 424 23. Bergantini L, d'Alessandro M, Cameli P, Cavallaro D, Gangi S, Cekorja B, et al. NK and T
- 425 Cell Immunological Signatures in Hospitalized Patients with COVID-19. Cells. 2021; 10:
- 426 3182.
- 427 24. Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, et al. Temporal changes
- in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19.
- 429 Clinical Immunology. 2022; **237**: 108991.
- 430 25. Shenoy AT, Lyon De Ana C, Arafa EI, Salwig I, Barker KA, Korkmaz FT, et al. Antigen
- presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier
- 432 immunity. Nat Commun. 2021; **12**: 5834.
- 433 26. Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CML. Cytotoxic CD4 T
- 434 Cells—Friend or Foe during Viral Infection? Front Immunol. 2017; 8: 19.

- 435 27. Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance
- of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell. 2020;
- **183**: 1340-1353.e16.
- 438 28. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-
- mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive
- study. Lancet Infect Dis. 2020; **20**: 1135–40.
- 441 29. He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalier N, et al. Circulating Precursor
- 442 CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody
- Responses upon Antigen Reexposure. Immunity. 2013; **39**: 770–81.
- 444 30. Dan JM, Havenar-Daughton C, Kendric K, Al-kolla R, Kaushik K, Rosales SL, et al.
- Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving
- antibody deficiency and aberrant TFH cells. Sci Transl Med. 2019; **11**: 3776.
- 447 31. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of
- Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell. 2020;
- **183**: 143-157.e13.
- 450 32. Sun J, Tang X, Bai R, Liang C, Zeng L, Lin H, et al. The kinetics of viral load and antibodies
- to SARS-CoV-2. Clinical Microbiology and Infection. 2020; **28**: 1690.e1-1690.e4.
- 452 33. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Functional Exhaustion
- of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;
- **11**: 827.
- 455 34. Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation
- and Function. Front Immunol. 2017; **8**: 194.
- 457 35. Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, et al.
- 458 Integrated immune dynamics define correlates of COVID-19 severity and antibody responses.
- 459 Cell Rep Med. 2021; **2**: 100208.

- 460 36. Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, et al.
- 461 Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell.
- 462 2022; **185**: 493-512.e25.
- 463 37. Kang CK, Han GC, Kim M, Kim G, Shin HM, Song KH, et al. Aberrant hyperactivation of
- 464 cytotoxic T-cell as a potential determinant of COVID-19 severity. International Journal of
- 465 Infectious Diseases. 2020; **97**: 313–21.
- 466 38. Jiang Y, Wei X, Guan J, Qin S, Wang Z, Lu H, et al. COVID-19 pneumonia: CD8+ T and NK
- 467 cells are decreased in number but compensatory increased in cytotoxic potential. Clinical
- 468 Immunology. 2020; **218**: 108516.
- 469 39. Chen Q, Yu B, Yang Y, Huang J, Liang Y, Zhou J, et al. Immunological and inflammatory
- profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int
- 471 Immunopharmacol. 2021; **97**: 107685.
- 472 40. Rha MS, Jeong HW, Ko JH, Choi SJ, Seo IH, Lee JS, et al. PD-1-Expressing SARS-CoV-2-
- Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19.
- 474 Immunity. 2021; **54**: 44-52.e3.
- 475 41. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates
- of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021; **590**: 630–634.
- 47. Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate V v., Lang H, Lazarski CA, et
- al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody
- 479 Deficiency. J Clin Immunol. 2021; **41**: 1146–53.
- 480 43. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells
- contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;
- **482 27**: 1280–9.
- 483 44. Wauters E, van Mol P, Garg AD, Jansen S, van Herck Y, Vanderbeke L, et al. Discriminating
- 484 mild from critical COVID-19 by innate and adaptive immune single-cell profiling of
- bronchoalveolar lavages. Cell Res. 2021; **31**: 272–90.

- 486 45. Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Pili Floury S, et al. COVID-19
- patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.
- 488 Journal of Infection. 2021; **82**: 282–327.
- 489 46. Khoo WH, Jackson K, Phetsouphanh C, Zaunders JJ, Alquicira-Hernandez J, Yazar S, et al.
- 490 Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with
- 491 mild/asymptomatic COVID-19. Clinical Immunology. 2023; **246**: 109209.
- 492 47. Gao Y, Ding M, Dong X, Zhang J, Kursat Azkur A, Azkur D, et al. Risk factors for severe
- and critically ill COVID 19 patients: A review. Allergy. 2021; **76**: 428–55.
- 494 48. Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human
- vaccine immune responses. Immunity & Ageing. 2019; **16**.
- 496 49. Jalali S, Harpur CM, Piers AT, Auladell M, Perriman L, Li S, et al. A high ☐ dimensional
- cytometry atlas of peripheral blood over the human life span. Immunol Cell Biol. 2022; **100**:
- 498 805–821.
- 499 50. Zheng Y, Liu X, Le W, Xie L, Li H, Wen W, et al. A human circulating immune cell
- landscape in aging and COVID-19. Protein Cell. 2020; 11: 740-770.
- 501 51. Ashhurst TM, Marsh□ Wakefield F, Putri GH, Spiteri AG, Shinko D, Read MN, et al.
- Integration, exploration, and analysis of high dimensional single cell cytometry data using
- 503 Spectre. Cytometry Part A. 2022; **101**: 237–53.
- 504 52. Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t-
- 505 SNE for improved visualization of single-cell RNA-seq data. Nat Methods. 2019; **16**: 243–
- 506 245.

- 507 53. Marsh Wakefield F, Juillard P, Ashhurst TM, Juillard A, Shinko D, Putri GH, et al.
- Peripheral B□cell dysregulation is associated with relapse after long term quiescence in
- patients with multiple sclerosis. Immunol Cell Biol. 2022; **100**: 453–467.

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532 533

534

535

536

537

538

Figure Legends Figure 1. Variance in the T cell compartment explained by COVID-19 severity. A) Principal component analysis based on the relative abundance of 38 T cell populations in patients with asymptomatic to critical COVID-19 (n = 35). Patient disease severity overlay on principal component analysis where non-overlapping disease states represent a difference in the relative abundance of T cell populations between groups. B) Variable contribution plot visualising the T cell populations that contribute to the principal components. Arrow direction represents correlation, where opposing direction is negative and adjacent arrows represent positive correlation between variables. Differences between groups determined by FDR. Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A) FIt-SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n = 3) patient. **B)** FIt-SNE visualisation of alterations in proportion of metaclusters making up the T cell compartment between severe and critical disease. C) Heatmap plot showing the relative expression of each marker on self-organised map metaclusters. **D)** Partial Least Squares Discriminant Analysis of relative frequencies of 20 non-redundant CD4⁺ and CD8⁺ T cell populations defined by automatic clustering. E) Christmas tree plot visualising the variables contributing to variance between severe and critical disease as determined by PLS-DA F) Nonparametric Mann-Whitney U test of proportions of metaclusters between severe and critical infection patients; error lines represent median \pm interquartile range. Figure 3. Differentiation status of CD4⁺ and CD8⁺ T cell compartments. A) Summary bar plots representing frequency of CD4⁺ and CD8⁺ T cell naïve and memory subsets between disease states defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} (CCR7 CD45RO). B) Frequency of CD4⁺ and CD8⁺ T_N and T_{EMRA} subsets C) Frequency of CD4⁺ and CD8⁺ T_{EMRA} cells expressing HLA-DR and PD-1. **D**) Frequency of total T_{FH} cells defined by CXCR5^{hi}CD4⁺ phenotype, and CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ cT_{FH} cells. Difference between

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent $median \pm interquartile range.$ Figure 4. Cytotoxic CD4⁺ and CD8⁺ T cells are expanded in critical infection. A) Frequency of GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. **B)** Frequency of GZMB⁺PFN⁺ non-T_{FH} cells (CXCR5^{-/lo}) and T_{FH} cells (CXCR5^{hi}) as a proportion of all CD4⁺ T cells C) Frequency of GZMB⁺PFN⁺ CD4⁺ T_{EMRA} cells as a proportion of parent **D**) Summary bar plot representing the differentiation status of total CD4⁺ non-T_{FH} cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T cells defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} (CCR7 CD45RO) in critical infection patients (n = 3). E) Summary bar plot representing the differentiation status of total CD4⁺ T_{FH} (CXCR5⁺) cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T_{FH} cells by CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ (cT_{FH}) cell phenotype in critical infection patients (n = 3). **F**) XY plot of correlation between GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells as a proportion of total CD4⁺ and CD8 T⁺ cells, respectively. Difference between groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent median \pm interquartile range.




Figure 1. Variance in the T cell compartment explained by COVID-19 severity. A) Principal component analysis based on the relative abundance of 38 T cell populations in patients with asymptomatic to critical COVID-19 (n = 35). Patient disease severity overlay on principal component analysis where non-overlapping disease states represent a difference in the relative abundance of T cell populations between groups. B) Variable contribution plot visualising the T cell populations that contribute to the principal components. Arrow direction represents correlation, where opposing direction is negative and adjacent arrows represent positive correlation between variables. Differences between groups determined by FDR.




Figure 2. Unbiased clustering of T cell compartment in severe and critical patients. A) FIt-SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n = 3) patient. **B)** FIt-SNE visualisation of alterations in proportion of metaclusters making up the T cell compartment between severe and critical disease. **C)** Heatmap plot showing the relative expression of each marker on self-organised map metaclusters. **D)** Partial Least Squares Discriminant Analysis of relative proportions of 20 non-redundant CD4⁺ and CD8⁺ T cell populations defined by automatic clustering. **E)** Christmas tree plot visualising the variables contributing to variance between severe and critical disease as determined by PLS-DA **F)** Non-parametric Mann-Whitney U test of proportions of metaclusters between severe and critical infection patients; error lines represent median ± interquartile range.




Figure 3. Differentiation status of CD4⁺ and CD8⁺ T cell compartments. **A**) Summary bar plots representing frequency of CD4⁺ and CD8⁺ T cell naïve and memory subsets between disease states defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} (CCR7⁻CD45RO⁻). **B**) Frequency of CD4⁺ and CD8⁺ T_N and T_{EMRA} subsets **C**) Frequency of CD4⁺ and CD8⁺ T_{EMRA} cells expressing HLA-DR and PD-1. **D**) Frequency of total T_{FH} cells defined by CXCR5^{hi}CD4⁺ phenotype, and CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ c T_{FH} cells. Difference between groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent median \pm interquartile range.






Figure 4. Cytotoxic CD4⁺ and **CD8**⁺ **T cells are expanded in critical infection.** A) Frequency of GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells across disease states. B) Frequency of GZMB⁺PFN⁺ non-T_{FH} cells (CXCR5^{-/lo}) and T_{FH} cells (CXCR5^{-/lo}) as a proportion of all CD4⁺ T cells C) Frequency of GZMB⁺PFN⁺ CD4⁺ T_{EMRA} cells as a proportion of parent D) Summary bar plot representing the differentiation status of total CD4⁺ non-T_{FH} cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T cells defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} (CCR7⁻CD45RO⁻) in critical infection patients (n = 3). E) Summary bar plot representing the differentiation status of total CD4⁺ T_{FH} (CXCR5⁺) cells and cytotoxic (GZMB⁺PFN⁺) CD4⁺ T_{FH} cells by CCR7⁺PD-1⁻ and CCR7⁻PD-1⁺ (cT_{FH}) cell phenotype in critical infection patients (n = 3). F) Pearson correlation between GZMB⁺PFN⁺ CD4⁺ and CD8⁺ T cells as a proportion of total CD4⁺ and CD8 T⁺ cells, respectively. Difference between groups determined by non-parametric Kruskal-Wallis, with comparison of the rank mean of experimental groups by Original FDR method of Benjamini and Hochberg; error bars represent median ± interquartile range.



Supplementary Figure 1. Gating strategy for T cells subsets. Human peripheral blood mononuclear cells (PBMCs) were analysed by spectral cytometry. **A)** Dead cells, cell aggregates, and myeloid cells were excluded by LIVE/DEAD, time, FSC-H, FSC-A, and SSC-A. T cells were isolated by CD3⁺CD19⁻ and CD3⁺CD56⁻ phenotype to exclude B cells and NKT cells, respectively. **B)** T cells were divided into CD4⁺ and CD8⁺ T cells. CD4⁺ T cells were divided further into CXCR5^{-/lo} CD4⁺ non-T_{FH} cells and CXCR5^{hi} T_{FH} cells. T_{FH} cells were defined as cT_{FH} by CCR7⁻PD-1⁻ and as CCR7⁺PD-1⁻ cells. CD4⁺ non-T_{FH} and CD8⁺ T cells were divided into naïve/memory subsets defined as T_N (CCR7⁺CD45RO⁻), T_{CM} (CCR7⁺CD45RO⁺), T_{EM} (CCR7⁻CD45RO⁺), and T_{EMRA} (CCR7⁻CD45RO⁻). Flow plots of representative non-infected control sample COVIMM_093 and performed in FlowJo v10.8.1.



Supplementary Figure 2. Expression of lineage and functional markers on FIt-SNE of metaclusters. Relative expression of cellular marker expression on FIt-SNE visualisation of FlowSOM automatic clustering of a subsample of T cells from each severe (n = 5) and critical (n = 3) patient.

624 Supplementary Table 1. Patient clinical characteristics

Peak disease status (n)	Median age (range)	Days post positive swab (range)
Asymptomatic (5)	30 (25-51)	11 (5-32)
Mild (18)	31 (12-60)	15 (5-49)
Moderate (4)	58 (55-79)	21 (14-28)
Severe (5)	49 (24-69)	14 (14-112)
critical (3)	65 (59-65)	28 (28)
Total	35 (12-79)	14 (5-12)

Product	Fluorophore	Clone	Detector	Species raised in	Source
CD3	BUV395	SK7	UV375_C	Mouse	BD Horizon TM
Invitrogen LIVE/DEAD TM Fixable Blue Dead Cell Stain Kit, for UV excitation	N/A	N/A	UV450	Mouse	Invitrogen
CD8^{\dagger}	BUV496	RPA-T8	UV514	Mouse	BD Horizon TM
PD-1 ^{†‡}	BUV737	EH12.2	UV737_	Mouse	BD Horizon TM
CD19	BV510	HIB19	V510_	Mouse	BioLegend [®]
CD56	BV605	NCAM16.2	V598	Mouse	BD Biosciences [©]
HLA-DR ^{†‡}	BV650	G46-6	V660_C	Mouse	BD Biosciences [©]
Ki-67 ^{†‡}	BV711	Ki67	V720	Mouse	BioLegend [®]
CD45RO [†]	BV786	UCHL1	V780_A	Mouse	BioLegend [®]
CD4 [†]	PerCPCy5.5	RPA-T4	B695_A	Mouse	BioLegend [®]
Perforin ^{†‡}	PE	B-D48	YG582_D	Mouse	BioLegend [®]
CD197(CCR7) [†]	PECy7	G043H7	YG780_A	Mouse	BioLegend [®]
Granzyme B ^{†‡}	APC	QA16A02	R660_C	Mouse	BioLegend [®]
CXCR5 [†]	AF647	RF8B2	R679	Rat	BD Biosciences [©]

⁶²⁶ Supplementary Table 2. Antibody Panel

627 [†]Markers used for automatic clustering; [‡] Intracellular markers